Download PDF

Human Molecular Genetics

Publication date: 2017-05-01
Volume: 26 Pages: 1656 - 1669
Publisher: IRL Press

Author:

Demirsoy, Seyma
Martin, Shaun ; Motamedi, sahar ; van Veen, Sarah ; Holemans, Tine ; Van den Haute, Chris ; Jordanova, A ; Baekelandt, Veerle ; Vangheluwe, Peter ; Agostinis, Patrizia

Keywords:

Science & Technology, Life Sciences & Biomedicine, Biochemistry & Molecular Biology, Genetics & Heredity, KUFOR-RAKEB SYNDROME, ALPHA-SYNUCLEIN, PARKINSONS-DISEASE, LYSOSOMAL DYSFUNCTION, QUALITY-CONTROL, MELANOMA, DEFICIENCY, AUTOPHAGY, PARK9, LEADS, Autophagy, Cell Line, Tumor, Endosomes, Humans, Lysosomes, Mutation, Parkinson Disease, Parkinsonian Disorders, Phosphatidylinositol Phosphates, Protein Transport, Proton-Translocating ATPases, Stress, Physiological, 06 Biological Sciences, 11 Medical and Health Sciences, 3105 Genetics

Abstract:

ATP13A2 (also called PARK9), is a transmembrane endo-/lysosomal-associated P5 type transport ATPase. Loss-of-function mutations in ATP13A2 result in the Kufor-Rakeb Syndrome (KRS), a form of autosomal Parkinson's disease (PD). In spite of a growing interest in ATP13A2, very little is known about its physiological role in stressed cells. Recent studies suggest that the N-terminal domain of ATP13A2 may hold key regulatory functions, but their nature remains incompletely understood. To this end, we generated a set of melanoma and neuroblastoma cell lines stably overexpressing wild-type (WT), catalytically inactive (D508N) and N-terminal mutants, or shRNA against ATP13A2. We found that under proteotoxic stress conditions, evoked by the proteasome inhibitor Bortezomib, endo-/lysosomal associated full-length ATP13A2 WT, catalytically-inactive or N-terminal fragment mutants, reduced the intracellular accumulation of ubiquitin-conjugated (Ub) proteins, independent of autophagic degradation. In contrast, ATP13A2 silencing increased the intracellular accumulation of Ub-proteins, a pattern also observed in patient-derived fibroblasts harbouring ATP13A2 loss-of function mutations. In treated cells, ATP13A2 evoked endocytic vesicle relocation and increased cargo export through nanovesicles. Expression of an ATP13A2 mutant abrogating PI(3,5)P2 binding or chemical inhibition of the PI(3,5)P2-generating enzyme PIKfyve, compromised vesicular trafficking/nanovesicles export and rescued intracellular accumulation of Ub-proteins in response to proteasomal inhibition. Hence, our study unravels a novel activity-independent scaffolding role of ATP13A2 in trafficking/export of intracellular cargo in response to proteotoxic stress.